Chanhyun Park, Ph.D., M.Pharm., M.Ed., R.Ph.

Selected Recent Publications
*Denotes student(s)/trainee(s) at the time of the study.

CORE Area: Patient-Centered Outcomes Research

Liu YS*, Barner JC, Lawson KL, Liu Y, Park C. Cardioprotective effectiveness of sodium-glucose cotransporter-2 inhibitors in early breast cancer following anthracycline- or trastuzumab-based chemotherapy. Therapeutic Advances in Medical Oncology.  2025 Sep 23:17:17588359251378245. doi: 10.1177/17588359251378245.

Le N*, Avanceña ALV, Liu Y, Shen C, Park C. Mediating effects of social and clinical factors on racial disparities in cardiovascular outcomes following anthracycline therapy in older women with breast cancer. Journal of Geriatric Oncology. 2025 Aug 5;16(7):102333. doi: 10.1016/j.jgo.2025.102333.

Liu YS*, Liu Y, Park C. Association of cardiovascular disease with health-related quality of life among older women with early-stage breast cancer undergoing adjuvant endocrine therapy. Journal of Geriatric Oncology. 2023 Sep;14(7):101598. doi: 10.1016/j.jgo.2023.101598. 1.

Park C, Park SK*, Woo A*, Ng BP. Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: A U.S Medicare population-based study. Quality of Life Research. 2022 Jan 22. doi: 10.1007/s11136-021-03059-x. 

Park C, Briesacher BA, Kim D. Association of social isolation of long-term care facilities in the United States with 30-day mortality. JAMA Network Open. 2021;4(6):e2113361. doi: 10.1001/jamanetworkopen.2021.13361.

CORE Area: Healthcare Systems Research

Ng BP, Hawkins GT, Massey M, LaManna JB, Park C. Digital divide among beneficiaries and Medicare diabetes prevention program. American Journal of Preventive Medicine. 2024 Jun 22:S0749-3797(24)00216-2. doi: 10.1016/j.amepre.2024.06.019.

Park C, Chang A, Ng BP, Young GJ. Cost-related medication nonadherence among Medicare beneficiaries with cardiovascular disease risk factors: the role of comprehension of the Medicare program and its prescription drug benefits. Journal of Evaluation in Clinical Practice. 2023 Feb;29(1):136-145. doi: 10.1111/jep.13745.

Park C, Ng BP, Kim K. Inability to access to healthcare due to COVID-19 among elderly Medicare beneficiaries in the United States. American Journal of Managed Care. 2022;28(2):75-80.

Ng BP, Park C. The role of media sources for COVID-19 information on engaging in recommended preventive behaviors among Medicare beneficiaries aged ≥ 65 years. Journal of Gerontology: Social Science. 2021 May 8;gbab083. doi: 10.1093/geronb/gbab083. 

Ng BP, Park C. Accessibility of telehealth services among Medicare beneficiaries aged ≥ 65 years during COVID-19.  Preventing Chronic Disease. 2021 Jul 1;18:E65. doi: 10.5888/pcd18.210056.

CORE Area: Health Economics and Outcomes Research

Park C, Liu YS*, Kenawy AS*, Lin YH*, Liu Y, Heo JH. Cardiovascular adverse events and associated costs of CDK4/6 inhibitors in patients with breast cancer. Journal of the National Comprehensive Cancer Network. 2025 Apr 18;23(5):e257001. doi: 10.6004/jnccn.2025.7001.

Byun JY*, Aiyeolemi AA*, Qdaisat A, Park C. Association between epidermal growth factor receptor–tyrosine kinase inhibitors and venous thromboembolism among older patients with advanced non–small cell lung cancer. Cancer. 2024 Jun 7. doi: 10.1002/cncr.35424.

Han S*, Sohn TJ*, Ng BP, Park C. Predicting unplanned readmission due to cardiovascular disease in hospitalized patients with cancer: a machine learning approach. Scientific Reports. 2023 Aug 18;13(1):13491. doi: 10.1038/s41598-023-40552-4.

Park C, Heo JH, Mehta S, Han S*, Spencer JC. Adherence to adjuvant endocrine therapy and survival among older women with early-stage hormone receptor-positive breast cancer. Clinical Drug Investigation. 2023 Mar;43(3):167-176. doi: 10.1007/s40261-023-01247-w. 

Park C, Park SK*, Upshaw JN, Schonberg MA. In-hospital mortality, length of stay, and hospital costs for hospitalized breast cancer patients with comorbid-heart failure in the USA. Current Medical Research and Opinion. 2022;37(12):2043-2047. doi: 10.1080/03007995.2021.1980775.

Graduate Courses

• PGS 384S Introduction to Epidemiology (Topic: Measures, Study Design, Bias, Machine Learning)
• PGS 393T Pharmacoeconomics (Topic: Decision Analysis, Markov Model)
• PGS 390J Data Analysis in Healthcare (Topic: Tables and Figures)
• PGS 196S Seminar in Pharmacy (Topic: Database in Health Outcomes Research)

Pharm.D. Courses

• PHM 394F Principles in Pharmacoeconomics and Pharmacy Management (Topic: Costs, Cost-Minimization Analysis, Cost-Benefit Analysis)

Significant/Recent Activities

National and International Service Activities

• Member, Cancer and Aging Research Group (CARG) - Health Services Core
• Member, Journal of Managed Care & Specialty Pharmacy (JMCP) - Editorial Advisory Board
• Mentor, Academy of Managed Care Pharmacy (AMCP) - Peer Review Academy
• Mentor, International Society for Pharmacoepidemiology (ISPE) - Peer Mentoring Program

University/College Service Activities

• Advisor, UT AMCP Student Chapter
• Advisor, UT ISPE Student Chapter
• Mentor, UTeams

Dr. Park and her mentees collaborate with external clinical and methodological collaborators through the C-MORE (Cardio-Metabolic Oncology Research and Evaluation for Health Outcomes) research group, which aims to “see more” where cardio-metabolic disease and oncology meet through real-world evidence to advance health outcomes. 

Recent Research Awards in C-MORE Research Group

• Spotlight Poster (Mentee: Nguyen Le) - 2025 International Society for Pharmacoepidemiology (ISPE) Annual Meeting
• Best Student Poster Research Presentation (Mentee: Ted Sohn) - 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting
• Student Travel Grant Award (Mentees: Ted Sohn, Yeijin Kim) - 2025 ISPOR Annual Meeting
• Best Graduate Student Poster (Mentee: Li-Wei Wu) - 2025 Academy of Managed Care Pharmacy (AMCP) Annual Meeting
• Student Travel Grant Award (Mentee: Yi-Shao Liu) - 2024 ISPOR Annual Meeting
• Poster Tour (Mentee: Sola Han) - 2023 ISPOR Annual Meeting

Recent Publications in C-MORE Research Group
*Denotes mentee(s) at the time of the study.

Cardio-Oncology (Breast Cancer Focus)

Park C, Liu YS*, Kenawy AS*, Lin YH*, Liu Y, Heo JH. Cardiovascular adverse events and associated costs of CDK4/6 inhibitors in patients with breast cancer. Journal of the National Comprehensive Cancer Network. 2025 Apr 18;23(5):e257001. doi: 10.6004/jnccn.2025.7001.

Liu YS*, Barner JC, Lawson KL, Liu Y, Park C. Cardioprotective effectiveness of sodium-glucose cotransporter-2 inhibitors in early breast cancer following anthracycline- or trastuzumab-based chemotherapy. Therapeutic Advances in Medical Oncology.  2025 Sep 23:17:17588359251378245. doi: 10.1177/17588359251378245.

Le N*, Avanceña ALV, Liu Y, Shen C, Park C. Mediating effects of social and clinical factors on racial disparities in cardiovascular outcomes following anthracycline therapy in older women with breast cancer. Journal of Geriatric Oncology. 2025 Aug 5;16(7):102333. doi: 10.1016/j.jgo.2025.102333.

Liu YS*, Liu Y, Park C. Association of cardiovascular disease with health-related quality of life among older women with early-stage breast cancer undergoing adjuvant endocrine therapy. Journal of Geriatric Oncology. 2023 Sep;14(7):101598. doi: 10.1016/j.jgo.2023.101598. 1.

Liu YS*, Dong K*, Park C. Risk of cardiovascular events with cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors among patients with advanced breast cancer: A systematic review and network meta-analysis. Reviews in Cardiovascular Medicine. 2023 Nov 9;24(11):309. doi: 10.31083/j.rcm2411309.

Park C, Park SK*, Upshaw JN, Schonberg MA. In-hospital mortality, length of stay, and hospital costs for hospitalized breast cancer patients with comorbid-heart failure in the USA. Current Medical Research and Opinion. 2022;37(12):2043-2047. doi: 10.1080/03007995.2021.1980775.

Cardio-Oncology (Lung Cancer Focus)

Kim Y*, Lee J, Suh HS, Park C. Cardiovascular and cancer-specific mortality in older patients with advanced NSCLC following the introduction of immuno-oncology therapies. Journal of Geriatric Oncology.

Kim Y*, Liu Y, Suh HS, Park C. Factors associated with cause-specific mortality in older patients with advanced NSCLC treated with PD-1 inhibitors: A US Population-based cohort study. Cancer Control. 2025 Jan-Dec:32:10732748251380932. doi: 10.1177/10732748251380932.

Byun JY*, Aiyeolemi AA*, Qdaisat A, Park C. Association between epidermal growth factor receptor–tyrosine kinase inhibitors and venous thromboembolism among older patients with advanced non–small cell lung cancer. Cancer. 2024 Jun 7. doi: 10.1002/cncr.35424.

Byun JY*, Han S*, Liu Y, Park C. Sex-specific risk of heart failure and acute myocardial infarction associated with osimertinib in older patients with non-small cell lung cancer. Therapeutic Advances in Medical Oncology. doi: 10.1177/1758835924126472

Byun JY*, Han S*, Qdaisat A, Park C. Long QT syndrome after using EGFR-TKIs in older patients with advanced non-small cell lung cancer. Expert Opinion on Drug Safety. 2024 Aug;23(8):1007-1015. doi: 10.1080/14740338.2023.2294924.

Cardio-Oncology (Other Cancer Focus)

Le N*, Han S*, Kenawy AS*, Kim Y*, Park C. Machine learning-based prediction of unplanned readmission due to major adverse cardiac events among hospitalized patients with blood cancers. Cancer Control. 2025 Jan-Dec:32:10732748251332803. doi: 10.1177/10732748251332803.

Park SK*, Park L*, Silverman C*, Heo JH, Park C. Association of congestive heart failure with hospital outcomes among renal cancer patients in the United States: Analysis of Nationwide Inpatient Sample. Expert Review of Pharmacoeconomics & Outcomes Research. 2021;21(3):395-402. doi: 10.1080/14737167.2021.1897576.

Yu A*, Thaliffdeen R*, Park SK*, Park C. Hospital outcomes and costs for prostate cancer patients with comorbid heart failure by age group: An analysis of the US Nationwide Inpatient Sample. Journal of Evaluation in Clinical Practice. 2023 Sep;29(6):1016-1024. doi: 10.1111/jep.13869.

Cardio-Oncology (Overall Cancer)

Han S*, Sohn TJ*, Ng BP, Park C. Predicting unplanned readmission due to cardiovascular disease in hospitalized patients with cancer: a machine learning approach. Scientific Reports. 2023 Aug 18;13(1):13491. doi: 10.1038/s41598-023-40552-4. 

Han S*, Sohn TJ*, Avanceña ALV, Park C. Rate, timing, and duration of unplanned readmissions due to cardiovascular diseases among hospitalized patients with cancer in the United States. Reviews in Cardiovascular Medicine. 2023 Nov 23;24(11):326. doi: 10.31083/j.rcm2411326.

Park C, Han S*, Mehta S*, Litten KP, Ng BP. Prevalence of primary and secondary hypertension among hospitalized patients with cancer in the United States. Chronic Illness. 2023 Aug 22:17423953231196613. doi: 10.1177/17423953231196613.